Table 2.
Treatments of SCD patients (n = 1,364) and distribution according to ethnicity and genotype.
| Therapya | Pts (%) | M vs. F | African vs. Caucasian vs. African-American | SS, No. (%) | S/β°, No. (%) | S/β+, No. (%) | SC, No. (%) | p-value |
|---|---|---|---|---|---|---|---|---|
| CTR | 292 (21.4) | 152/140 | 94/181/14 | 139 (49.5) | 64 (22.8) | 69 (24.6) | 9 (3.2) | <0.001 |
| ATR | 196 (14.4) | 92/104 | 116/69/10 | 103 (53.1) | 26 (13.4) | 32 (16.5) | 33 (17) | <0.001 |
| HC | 497 (36.4) | 273/224 | 238/246/11 | 268 (54.7) | 110 (22.4) | 96 (19.6) | 16 (3.3) | <0.001 |
| None | 379 (27.8) | 196/183 | 280/91/7 | 155 (42.6) | 30 (8.2) | 64 (17.6) | 115 (31.6) | <0.001 |
| bATR/CTR → HC | 236 (17.3) | 129/107 | 120/109/7 | 138 | 53 | 37 | 3 | – |
| bHC → CTR | 14 (1.0) | 8/6 | 6/7/1 | 9 | 2 | 2 | 1 | – |
a
The sum of partial counts may not correspond to the total in the case of different and/or not defined ethnicity/genotype.
b
Subset of 250 patients for whom it was possible to follow the timing of therapy.
A total of 100 patients under HC were transfused for the clinical management of acute vaso-occlusive events (VOCs).
ATR, acute transfusion regimen; CTR, chronic transfusion regimen; F, female; HC, Hydroxycarbamide; M, male; Pts, patients.